Bronchodilator Drugs - Bosnia and Herzegovina

Bosnia and Herzegovina

The Bronchodilator Drugs market in Bosnia and Herzegovina is expected to witness a significant increase in revenue, projected to reach US$4.40m in 2024.
Furthermore, there is an anticipated annual growth rate (CAGR 2024-2028) of 3.71%, which will contribute to a market volume of US$5.09m by 2028.
It is worth noting that in a global context, United States is expected to generate the highest revenue in this market, amounting to US$17,340.00m in 2024.
The demand for bronchodilator drugs in Bosnia and Herzegovina is on the rise due to the increasing prevalence of respiratory diseases in the country.

Key regions: Europe, India, Canada, Italy, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

Bronchodilator drugs, which are used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease, are seeing a steady demand in Bosnia and Herzegovina.

Customer preferences: Patients in Bosnia and Herzegovina are increasingly opting for bronchodilator drugs due to the rising prevalence of respiratory diseases in the country. Additionally, the convenience of using inhalers as opposed to traditional medication methods is also contributing to the growth in demand.

Trends in the market: The bronchodilator drugs market in Bosnia and Herzegovina is expected to see a steady growth in the coming years. The market is being driven by factors such as an aging population, increasing awareness about respiratory diseases, and the availability of advanced drugs. The market is also witnessing an increase in the number of generic drugs, which are more affordable for patients.

Local special circumstances: Bosnia and Herzegovina has a high prevalence of respiratory diseases, with asthma being one of the most common chronic diseases in the country. The country also has a high smoking rate, which is a major contributor to respiratory diseases. Additionally, the country has a relatively low GDP per capita, which is driving demand for affordable medication.

Underlying macroeconomic factors: The healthcare sector in Bosnia and Herzegovina is undergoing significant reforms, which are aimed at improving the quality of healthcare services in the country. The government is also investing in healthcare infrastructure, which is expected to boost the availability of healthcare services in the country. Additionally, the country's accession to the European Union is expected to bring about significant changes in the healthcare sector, which could impact the bronchodilator drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.